Figure 4.
Blockade of BCR signaling in ABC DLBCL with ibrutinib, an irreversible inhibitor of BTK. Shown is the pilot analysis of ABC DLBCL gene mutations and response to ibrutinib.
Blockade of BCR signaling in ABC DLBCL with ibrutinib, an irreversible inhibitor of BTK. Shown is the pilot analysis of ABC DLBCL gene mutations and response to ibrutinib.
